ngl: I’m excited about Johnson & Johnson’s new Center for U.S. Healthcare Policy Research, which is designed as a home for all the evidence-based policy analysis, original research, issue briefs, and the like that the company has been pushing out for the past decade. I’m excited for two reasons. First, it’s good to see pharmaceutical companies driving their own research agenda. The reality is that companies that are deeply embedded in the system tend to know the right questions to ask, because it’s informed by day-to-day business realities. That doesn’t give industry a particular monopoly on the truth, but it allows for a different set of perspectives, and perspectives that don’t necessarily get shared. Second, it’s good to see companies talking about policy research out loud. A lot of times, pharma policy arguments are made by proxy. But there is something direct and credible when those arguments are attached to a specific organization. It doesn't mean that they're going to win every policy debate, but it's good to have them in the arena. https://lnkd.in/dpS6aFne
Very smart move.
100% agree. It allows them to highlight the stories and data that are important to J&J instead of reacting to other narratives. And strategically, they can amplify perspectives from trade groups where there is alignment. Always better to be participating in the conversation and dialog - helps build trust in a fundamentally different way.
This approach goes back to the theory that if you aren't at the policymaking table, you are on the menu, Brian Reid. Issues of access, value, and innovation are not only not going away for the industry, but only increasing as the science and technology advance at a rapid pace.
Do you think PBMs will have to create their own research center now? 🙂